Expanding Access to Obesity Medications Could Avert 42,000 Deaths/Year
Impact of expanding access to GLP-1 receptor agonists, dual gastric inhibitory polypeptide and GLP-1 receptor agonists quantified
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.